CN105920017B - A kind of medical composition and its use for treating simple obesity - Google Patents
A kind of medical composition and its use for treating simple obesity Download PDFInfo
- Publication number
- CN105920017B CN105920017B CN201610405189.1A CN201610405189A CN105920017B CN 105920017 B CN105920017 B CN 105920017B CN 201610405189 A CN201610405189 A CN 201610405189A CN 105920017 B CN105920017 B CN 105920017B
- Authority
- CN
- China
- Prior art keywords
- lorcaserin
- sucrose fatty
- fatty ester
- pharmaceutical composition
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to a kind of medical composition and its uses for treating simple obesity, and in particular to a kind of using lorcaserin and sucrose fatty ester as the pharmaceutical composition of active constituents of medicine.Lorcaserin significant effect in terms of simple obesity is treated, but adverse reaction is larger, and based on this, lorcaserin and sucrose fatty ester are used in combination and are treated for obeisity by pharmaceutical composition creativeness of the present invention, wherein the ratio of the two is 1：0.1~100.The two reduces the clinical dosage that single medicine uses after being used in combination, so as to reduce the toxic side effect of drug, enhance therapeutic effect, has important clinical treatment meaning.
Description
Technical field
The present invention relates to a kind of medical composition and its uses for treating simple obesity, and in particular to one kind is with chlorine card
Color woods and the pharmaceutical composition that sucrose fatty ester is active constituents of medicine.
Background technology
Obesity (obesity) is a kind of chronic disease.Estimate that it is the most appearance that the mankind face at present according to the World Health Organization
It is easily ignored, but incidence is in a kind of disease steeply risen.In addition to the mankind, many pets can also suffer from obesity.Lactation is moved
Object storage hyperliposis (including people), so that health is affected.Obesity is one group of common, ancient metabolism disease
Group.When human body feed heat is more than consumption of calorie, for waste heat with storage as fat in internal, amount is more than normal physiological
Requirement, and up to certain value when develop into obesity then.The 15% of Normal Male Adults adipose tissue mass about percentage of liveweight~
18%, women accounts for 20%~25%.Increase with the age, body fat proportion accordingly increases.It is more than because body fat increase makes weight
Standard weight 20% or body mass index [BMI=weight (Kg)/(height)2(m2)] more than 24 it is known as obesity.As without apparent disease
Because can the person of seeking claim simple obesity；It is known as secondary obesity with clear and definite cause of disease person.
Obesity is many to the harm that the mankind bring, and not only influences quality of life, is also one huge to health
Threat, many complication such as a variety of angiocarpy can be triggered.Diabetes are a kind of most common complication of obesity.Beijing
The burnt graduate expert of East Sea traditional Chinese medicine defatting points out that the fasting blood-glucose of patient normally, it is small to feed 3-4 sometimes when obesity starts
When after patient be present with hypoglycemic reaction, caused by this is body Delayed onset insulin secretion.With the extension of fat medical history,
Patient gradually appears the performances such as sugar tolerance declines, postprandial blood sugar raises, fasting blood-glucose rise, ultimately results in the generation of diabetes.
The main reason for insulin level of this kind of diabetic is suitable with normal person, complicated with diabetes is 1) in obesity patient's body
Insulin receptor quantity reduce and insulin sensitivity decline is the principal element that causes complicated with diabetes.2) overweight people
Weight gain, body surface area increase, over-burden for islet cells, insulin secretion relative deficiency can also cause blood glucose level rises
It is high.As it can be seen that there is very close relationships between diabetes and obesity.
CNS inhibition class drug is that people develop the most a kind of slimming drugs of kind, but since people act on machine to it
System and the understanding of side effect are thorough not enough, result in the generation of a variety of tragedies.The drug also much developed do not go public or
It is disabled, such as mazindol, Sertraline, ecopipam, indoles, ring imidazolyl-indoles indoles substance.60 years last century
In generation, digitalis, thyroid hormone and amphetamine are used in mixed way once fashionable for a time, but because unreasonable proportioning uses, cause dead
The tragedy died occurs and is terminated.
In recent years, being used in combination for slimming medicine is approved again by people, be used in combination not only can effectively reduce it is single
The dosage of drug improves its drug safety, and can further enhance therapeutic effect.In June, 2012 FDA approvals
The Phentermine of VIVUS companies and the composite reagent of Topiramate can be listed as the slimming drugs of long-time service in the U.S..1998 10
The moon, Topiramate was ratified as antiepileptic to use by FDA, and now the mechanism of action as slimming drugs is also indefinite, may contain carbon
Acid anhydrides enzyme influences the sense of taste and inhibits the transmission of γ-aminobutyric acid (GABA), so as to reduce appetite.Utilize Phentermine and Topiramate
Be applied in combination, can not only reduce Topiramate usage amount, and more preferable than effect is used alone, it is less side effects.2014 9
Naltrexone/Bupropion combination agent of moon FDA approval Takeda and Orexigen companies joint research and development exploitation, as long-term auxiliary
Slimming medicine lists in the U.S..Naltrexone is the opiate receptor antagonist of the amount of a losing weight minimum, and inhibitory hormone is to cell
Effect, reduce intake.
During the lorcaserin of lorcaserin (lorcaserin) in June, 2012 FDA approval Arena and Eisai companies is used as
Long-term slimming drugs use lists in the U.S..Its mechanism of action：Excitomotor center action of nervous system serotonin 2c receptors control
Appetite, the side effects such as cardiac valves caused by avoiding serotonin 2b receptors and 2a receptors.By the FDA committees issue on
It finds there is potential cardiac valves side effect during the medicine later stage use, while is also as above breathed there are some adverse reactions
Road infection, headache, dizzy and nausea etc., the long-term use of medicine, which may have, potentially suffers from tumour, mental illness and angiocardiopathy
Danger, above-mentioned three kinds are potential dangerous also among clinical research and verification.Lorcaserin Central nervous mechanism of action is more
Add clearly, specific aim is stronger, security higher, is another accurate medicine of current central action class slimming drugs.
Lorcaserin has certain therapeutic effect in terms of simple obesity is treated, but since it is central action class
Slimming drugs still have higher toxic side effect, and how reducing its toxic side effect and enhancing its fat-reducing effect becomes medicine neck
The problem of concern is needed in domain, it will be that more obesity patients bring glad tidings effectively to solve the problems, such as this.Based on this, spy proposes this
Invention.
The content of the invention
The pharmaceutical composition of the present invention is made of lorcaserin and sucrose fatty ester and pharmaceutic adjuvant, due to two kinds of medicines
The mechanism of drug action of object is complementary, and the arbitrary proportioning of lorcaserin and sucrose fatty ester can be to obesity and Metabolic syndrome
The treatment and prevention of disease embody synergistic effect.The wherein described sucrose fatty ester is monoesters, diester, three esters or four esters.More
Preferably its monoesters.
The present inventor on this basis, screens to have obtained and acts synergistically more by numerous formulation test and pharmacological testing
Significant composition proportioning, accordingly, lorcaserin and the weight of sucrose fatty ester in pharmaceutical composition disclosed in this invention
Than for preferably 1：0.1~100, weight ratio still more preferably is 1：0.5~10.The agent of the pharmaceutical preparation of said composition
Type, can be according to general system well known in the art including solid pharmaceutical preparations such as ordinary tablet, dispersible tablet, sustained release tablets, capsule, granules
It is prepared by agent method.In pharmaceutical preparation produced by the present invention, in each preparation unit the effective quantity containing lorcaserin for 30mg~
150mg, further preferably 30mg~60mg；Effective quantity containing sucrose fatty ester is 75mg~300mg, further preferably
For 150mg~300mg.
The invention also discloses the pharmaceutical compositions using lorcaserin and sucrose fatty ester as medicament active composition to make
The purposes of standby treatment/prevention obesity drug.Pharmaceutical composition of the present invention is comprehensive for the prevention or treatment or metabolism of obesity
When closing the prevention and treatment of disease, preferably it is administered orally, pharmaceutical dosage form disclosed by the invention and other dosage forms can be used, it is excellent
Elect tablet as.During for bariatrician, the dosage of lorcaserin is 0.1mg/kgd~2.5mg/ in pharmaceutical composition
Kgd is preferably 0.5mg/kgd~1mg/kgd；The dosage of sucrose fatty ester is 0.25mg/kgd~10mg/
Kgd is preferably 1.5mg/kgd~5mg/kgd.
The present invention filters out and sucrose-fatty with synergy after lorcaserin use in conjunction from multi-medicament
Ester, by the pharmacodynamic study of the present invention, in an experiment it was unexpectedly observed that lorcaserin and sucrose fatty ester are used in combination
Not only there is apparent concertednesses in terms of serum total cholesterol, serum triglyceride and low density lipoprotein cholesterol is reduced
Effect, and compared with being used in combination of lorcaserin and Pravastatin, lipid-lowering effect becomes apparent, in increasing high density fat
In terms of protein cholesterol, also there is obvious advantage.
Shown by the research work in terms of pharmacology with a effective amount of lorcaserin or sucrose fatty ester phase is used alone
Than when with the composition of the present invention, during in particular by preferred proportioning, there is astonishing more preferable effect, while poison
Property do not increase, in the case where reaching identical lipid-lowering effect, two class drugs 5 are using greatly reducing the use of each drug
Dosage, this has been significantly reduced the adverse reaction of lorcaserin and the drug risk of sucrose fatty ester.
Specific embodiment
The preparation of 1 composite tablet of embodiment
Preparation process：The lorcaserin of recipe quantity, sucrose fatty ester, starch, microcrystalline cellulose is weighed to be uniformly mixed.Separately
Suitable 15% starch slurry is incorporated in mixed-powder, is uniformly mixed, softwood processed, wet grain is made by 18 mesh nylon mesh, 60
DEG C or so it is dry, dry granular moisture should be controlled below 1.5%.20 mesh sieve whole grains, then with magnesium stearate mixing, tabletting to get.
The preparation of 2 composite tablet of embodiment
Preparation process：In addition to auxiliary material is different, preparation method is the same as embodiment 1..
Embodiment 3
Preparation process：Lorcaserin crosses 100 mesh sieves, and hydroxypropyl cellulose -4M, microcrystalline cellulose cross 80 mesh sieves, weigh place
The lorcaserin and hydroxypropyl cellulose -4M, microcrystalline cellulose just measured are uniformly mixed, and it is appropriate to add in 8%PVP ethanol solutions
Granulation, 60 DEG C of dryings, 16 mesh sieves whole dry particl add in the magnesium stearate of recipe quantity in dry particl.
Preparation process：Sucrose fatty ester crosses 100 mesh sieves, and sodium carboxymethylcellulose, lactose cross 80 mesh sieves, weigh recipe quantity
Sucrose fatty ester and sodium carboxymethylcellulose, lactose be uniformly mixed, 95% ethanol solution for adding in 6%PVP is pelletized in right amount,
60 DEG C of dryings, 16 mesh sieves whole dry particl add in the magnesium stearate of recipe quantity in dry particl.
C, by above-mentioned a, two kinds of components of b are using bi-layer tablet press punching press up to double-layer tablets.
The preparation of 5 compound dispersed tablet of embodiment
Preparation process：Lorcaserin, sucrose fatty ester are weighed by recipe quantity, using microcrystalline cellulose as filler, crosslinking
Sodium carboxymethylcellulose, polyvinylpyrrolidone are disintegrant, and 60% ethanol solutions of 5%PVP are binder, and superfine silica gel powder is
Glidant, with fluid-bed marumerization, then tabletting to get.
The preparation of 6 composite tablet of embodiment
Preparation process：It is prepared by the common process of tablet to obtain the final product.
The preparation of 7 composite tablet of embodiment
Preparation process：It is prepared by the common process of tablet to obtain the final product.
The preparation of 8 compound granule of embodiment
Preparation process：The lorcaserin of recipe quantity, sucrose fatty ester, starch, dextrin, cane sugar powder is weighed to be uniformly mixed.
Separately suitable 80% ethyl alcohol is incorporated in mixed-powder, is uniformly mixed, softwood processed, wet grain is made by 18 mesh nylon mesh, 60
DEG C or so dry, 20 mesh sieve whole grains, dispense to get.
The preparation of 9 compound dispersed tablet of embodiment
Preparation process：Lorcaserin, sucrose fatty ester are weighed by recipe quantity, using microcrystalline cellulose as filler, crosslinking
Sodium carboxymethylcellulose, polyvinylpyrrolidone are disintegrant, and 60% ethanol solutions of 5%PVP are binder, and superfine silica gel powder is
Glidant, with fluid-bed marumerization, then tabletting to get.
10 compound of embodiment is to fat and hyperlipemia mouse influence
1. the preparation of animal model
4 week old KM mouse, half male and half female, southern Shandong pharmacy Experimental Animal Center provide, feed with high lipid food (high lipid food
It is formulated as casein 1kg, L-cysteine 15g, maltodextrin 0.75kg, sucrose 0.35kg, cellulose 0.25kg, soybean oil
0.15kg, lard 1.25kg).After raising 10 weeks, the mouse that weight is less than 60g is eliminated, then grouping administration.
2. grouping and administration
Modeling success rat is randomly divided into following each group according to weight：
Model group：The physiological saline of same volume
Lorcaserin group：12mg/(kg.d)
Sucrose fatty ester group：7.5mg/ (kg.d) sucrose fatty ester
Compound low dose group：0.7mg/ (kg.d) lorcaserins+1.75mg/ (kg.d) sucrose fatty ester
Compound middle dose group：3.5mg/ (kg.d) lorcaserins+10.5mg/ (kg.d) sucrose fatty ester
Compound high dose group：17.5mg/ (kg.d) lorcaserins+61mg/ (kg.d) sucrose fatty ester
Every group 8, still fed during administration with high lipid food, daily gavage three times, respectively 6：00、14：00、22：00 fills
Stomach, continuous 8 weeks.
3. Testing index
3.1 body weight determination
It weighed after administration the 2nd week every 2 weeks, the results show that since the 4th week, group and compound are high in compound
Group has significant difference or pole significant difference compared with model group；From the 6th week, low group of compound has significantly compared with model group
Sex differernce or pole significant difference, these show that compound each group has weight-reducing drug effect well.In addition, since the 4th week, compound
Each group gradually shows significant difference or pole significant difference compared with sucrose fatty ester group, and at the 8th week, compound was each
Group has significant difference or pole significant difference compared with group, these show to be united and applied in weight-reducing tool with sucrose fatty ester
There is good synergistic effect.Experimental result refers to table 1.
Influence (unit of the 1 compound each group of table to mouse weight：g)
* compared with model group, P ＜ 0.05；* is compared with model group, P ＜ 0.01；
# is compared with lorcaserin group, P ＜ 0.05；## is compared with lorcaserin group, P ＜ 0.01；
＆ is compared with sucrose fatty ester group, P ＜ 0.05；＆＆ is compared with sucrose fatty ester group, P ＜ 0.01；
3.2 lipid determination
After administration, serum total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), high density lipoprotein level are detected
White cholesterol (HDL-C), triglycerides (TG).The results show that T-CHOL, triglycerides, high-density lipoprotein cholesterol and
The level of low density lipoprotein cholesterol has pole significant difference compared with model group, with lorcaserin group or sucrose fatty ester
For group compared to also having significant difference or pole significant difference, this explanation is united and applied in sucrose fatty ester reduces blood fat tool
There is good synergistic effect.Experimental result refers to table 2.
Influence (mmol/L) of the 2 compound each group of table to lipid in mouse blood
| Group | n | TC | TG | HDL-C | LDL-C |
| Model group | 10 | 2.83±0.35 | 1.88±0.41 | 2.12±0.68 | 0.68±0.18 |
| Lorcaserin group | 10 | 2.72±0.34 | 1.60±0.29 | 2.72±0.93 | 0.63±0.14 |
| Sucrose fatty ester group | 10 | 2.49±0.26 | 1.35±0.34 | 2.86±0.72 | 0.56±0.09 |
| Low group of compound | 10 | 2.34±0.28**## | 1.26±0.29**## | 2.78±0.80* | 0.50±0.08**#& |
| Group in compound | 10 | 2.26±0.27**##& | 1.05±0.21**##& | 2.86±0.76* | 0.44±0.06**##&& |
| High group of compound | 10 | 2.15±0.20**##&& | 1.01±0.19**##& | 2.95±0.82* | 0.43±0.07**##&& |
* compared with model group, P ＜ 0.05；* is compared with model group, P ＜ 0.01；
# is compared with lorcaserin group, P ＜ 0.05；## is compared with lorcaserin group, P ＜ 0.01；
＆ is compared with sucrose fatty ester group, P ＜ 0.05；＆＆ is compared with sucrose fatty ester group, P ＜ 0.01
Claims (6)
1. a kind of pharmaceutical composition for treating simple obesity, by lorcaserin and sucrose fatty ester and pharmaceutic adjuvant group
Into；
The pharmaceutical composition is oral formulations；
Lorcaserin and the weight ratio of sucrose fatty ester are 1 in described pharmaceutical composition:0.5~10；
The effective quantity containing lorcaserin is 30mg ~ 150mg in each preparation unit of the oral formulations, contains sucrose fat
The effective quantity of acid esters is 75mg ~ 300mg.
2. pharmaceutical composition according to claim 1, which is characterized in that the sucrose fatty ester for monoesters, diester,
Three esters or four esters.
3. pharmaceutical composition according to claim 2, which is characterized in that the sucrose fatty ester is monoesters.
4. pharmaceutical composition according to claim 1, which is characterized in that the oral formulations for ordinary tablet, dispersible tablet,
Sustained release tablets, capsule or granule.
5. pharmaceutical composition according to claim 1, which is characterized in that contain in each preparation unit of the oral formulations
There is the effective quantity of lorcaserin for 30mg ~ 60mg, the effective quantity containing sucrose fatty ester is 150mg ~ 300mg.
6. pharmaceutical composition described in claim 1 is preparing the purposes for the treatment of/prevention obesity drug.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610405189.1A CN105920017B (en) | 2016-06-08 | 2016-06-08 | A kind of medical composition and its use for treating simple obesity |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610405189.1A CN105920017B (en) | 2016-06-08 | 2016-06-08 | A kind of medical composition and its use for treating simple obesity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105920017A CN105920017A (en) | 2016-09-07 |
| CN105920017B true CN105920017B (en) | 2018-06-05 |
Family
ID=56833589
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610405189.1A Active CN105920017B (en) | 2016-06-08 | 2016-06-08 | A kind of medical composition and its use for treating simple obesity |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105920017B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101094675A (en) * | 2004-11-05 | 2007-12-26 | 惠氏公司 | Formulations of [1,4]diazepino[6,7,1-ij]quinoline derivatives |
-
2016
- 2016-06-08 CN CN201610405189.1A patent/CN105920017B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101094675A (en) * | 2004-11-05 | 2007-12-26 | 惠氏公司 | Formulations of [1,4]diazepino[6,7,1-ij]quinoline derivatives |
Non-Patent Citations (2)
| Title |
|---|
| Lorcaserin, a selective 5-HT2C receptor agonist, decreases alcohol intake in female alcohol preferring rats;Amir H.Rezvani,et al.;《Pharmacology,Biochemistry and Behavior》;20140807;第125卷;第8-14页 * |
| 治疗肥胖的新药氯卡色林;石卫峰等;《中国新药杂志》;20141231;第23卷(第2期);第127-129和133页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105920017A (en) | 2016-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101940620B (en) | Medicinal composition for treating diabetes mellitus and application thereof | |
| KR101923840B1 (en) | Composition and medicinal product for reducing body weight and body fat, and use of said product | |
| CN102018832B (en) | Weight-reducing composition and preparation method thereof | |
| CN102205011A (en) | Medicinal composition with weight loss function | |
| CN103083557A (en) | Traditional Chinese medicine composition with functions of reducing blood pressure and blood fat | |
| WO2021109511A1 (en) | Anti-fatigue composition and preparation method therefor | |
| CN101607036B (en) | Application of Chinese medicinal composition on in preparing medicament for treating depression | |
| CN102872062A (en) | Medicinal composition for treating or preventing obesity and metabolic syndromes | |
| CN108420890B (en) | Composition with blood fat reducing effect and preparation method thereof | |
| CN105920017B (en) | A kind of medical composition and its use for treating simple obesity | |
| CN101491605A (en) | Combination with blood sugar reducing function and preparation method thereof | |
| AU2010358534A1 (en) | Anti-fatigue composition of plant material and preparation method, use and products thereof | |
| CN106349318B (en) | A kind of application of pentacyclic triterpene compound in obesity treating medicine is prepared | |
| CN107582866B (en) | Application method of dendrobium officinale and amlodipine in preparation of medicine for treating hypertension | |
| US11957726B2 (en) | Pharmaceutical composition for controlling blood sugar | |
| CN107951940B (en) | Blood pressure lowering medicine composition | |
| CN104721192A (en) | Pharmaceutical composition containing lorcaserin and medical application of pharmaceutical composition | |
| JP2001048802A (en) | Health auxiliary food effective for diabetes, method of using the same and food combination preparation effective for diabetes | |
| CN100579567C (en) | Use of Chinese medicine preparation in preparing medicine for defending coronary heart disease | |
| CN101491584A (en) | Combination with blood sugar reducing function and preparation method thereof | |
| CN102552481A (en) | Traditional Chinese medicinal composition with effects of smoothing collaterals and lowering blood pressure and preparation method thereof | |
| CN109731076B (en) | Medicine or food therapy preparation for preventing and treating spleen and stomach damp-heat syndrome based on preventive treatment theory | |
| CN109700818B (en) | Medicinal composition for losing weight and reducing blood fat and preparation method and application thereof | |
| JP4465963B2 (en) | Composition for preventing or improving hyperlipidemia | |
| CN105816470A (en) | Application of 20(R)-ginsenoside in preparation of medicine or health product for alleviating or/and treating diabetes and medicine thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CP03 | Change of name, title or address |
Address after: No. 6, Huafeng Road, Yonghe District, Guangzhou Economic and Technological Development Zone, Guangdong 510530 Patentee after: Guangdong Jiadele Technology Co.,Ltd. Address before: No. 6 Huafeng Road, Yonghe Economic Zone, Guangzhou Economic and Technological Development Zone, Guangdong Province, 510635 Patentee before: GUANGZHOU CARDLO BIOCHEMICAL TECHNOLOGY Co.,Ltd. |
|
| CP03 | Change of name, title or address |